Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.32 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.31 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.31 |
| ▸ | GNPAT | O15228 | 1/20 | 0.30 |
| ▸ | PAM | P19021 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23685458 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAPTKDM4ETHRBALOX15 | |
| SCHEMBL12537111 | 0.86 | ALDH1A1 (0.42) | ALDH1A1MAPTKDM4ETHRBALOX15 | |
| SCHEMBL10308608 | 0.86 | ALDH1A1 (0.42) | ALDH1A1MAPTKDM4ETHRBALOX15 | |
| SCHEMBL25454303 | 0.86 | ALDH1A1 (0.42) | ALDH1A1MAPTKDM4ETHRBALOX15 | |
| SCHEMBL12537168 | 0.83 | DPP4 (0.40) | ALDH1A1MAPTKDM4ETHRBALOX15 | |
| SCHEMBL25448139 | 0.80 | CTSC (0.34) | — | |
| SCHEMBL10308362 | 0.80 | KDM4E (0.45) | ALDH1A1MAPTKDM4ETHRBALOX15 | |
| SCHEMBL12537183 | 0.80 | ALDH1A1 (0.44) | ALDH1A1MAPTKDM4ETHRBALOX15 | |
| SCHEMBL20756564 | 0.79 | NOD1 (0.36) | ALDH1A1 | |
| SCHEMBL20122041 | 0.79 | NOD1 (0.50) | ALDH1A1MAPTKDM4ETHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202756-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | FRANKLIN RICHARD (GB) | 2012-08-09 | — | — | US | disclosed |
| US-20120184532-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | SHIRE LLC (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120178666-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2012-07-12 | — | — | US | disclosed |
| US-20110098278-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | SHIRE LLC (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110065796-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110028552-A1 | MEXILETINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | SHIRE LLC | 2011-02-03 | — | — | US | disclosed |
| US-20100286186-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286186-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | VIP, OPRL1, OPRK1 | ALDH1A1 1313/4885MAPT 1430/4885KDM4E 1873/4885 |
| US-20110098278-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | PEPD, VIP, GALR1 | ALDH1A1 3187/4885MAPT 365/4885KDM4E 2154/4885 |
| US-20120202756-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | OPRM1, UGT1A6, UGT1A4 | ALDH1A1 327/4885MAPT 1661/4885KDM4E 2296/4885 |
| US-20120184532-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | PEPD, VIP, GALR1 | ALDH1A1 3187/4885MAPT 365/4885KDM4E 2154/4885 |
| US-20120178666-A1 | PRODRUGS OF GUANFACINE | DNPEP, VIP, GDA | ALDH1A1 677/4885MAPT 1107/4885KDM4E 1653/4885 |
| US-20110028552-A1 | MEXILETINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | VIP, TRPV1, LNPEP | ALDH1A1 2722/4885MAPT 3854/4885KDM4E 1788/4885 |
| US-20110065796-A1 | PRODRUGS OF GUANFACINE | DNPEP, VIP, GDA | ALDH1A1 677/4885MAPT 1107/4885KDM4E 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.